KRAS mutation-driven O-GlcNAcylation of CLDN18.2 enhances the progression of pancreatic cancer and reduces the efficacy of CLDN18.2-targeted therapy
1. 系统已在2026-05-01 11:24:28对应助文件进行删除
2. 如有需要请重新发布求助信息
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI: 10.1136/gutjnl-2025-336277
文献链接: https://gut.bmj.com/lookup/doi/10.1136/gutjnl-2025-336277
其他信息:
出版社: BMJ
作者: Jing Liu; Xupeng Hou; Lin Li; Weiwei Bai; Tianxing Zhou; Moran Chen; Hu Yu; Hongxia Sun; Tingting Xu; Yifei Wang; Antao Chang; Yukuan Feng; Jun Yu; Chongbiao Huang; Yongjie Xie; Jihui Hao

